Cure My Disease

Don't miss your cure!

 Log in / Sign up

New TB drug cocktails aim to cut treatment time in half

NCT ID NCT05971602

Terminated Disease control Sponsor: Gates Medical Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This clinical trial tested whether combining several drugs—bedaquiline, OPC-167832, sutezolid, and either pretomanid or delamanid—could treat pulmonary tuberculosis in just 2 to 4 months instead of the standard 6 months. The study enrolled 93 adults with drug-sensitive or drug-resistant TB. Unfortunately, the trial was terminated early, so we have limited data on how well these shorter regimens work.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Combination of bedaquiline, OPC-167832, sutezolid, and either pretomanid or delamanid
What this could lead to
If successful, this could point toward shorter, simpler treatment regimens for tuberculosis, reducing the time patients need to take medication.
What could go wrong
The trial was terminated early, so results are limited. It was a phase 2 study with only 93 participants, meaning it is too early to know if these combinations are safe and effective for widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multidrug-resistant tuberculosis pulmonary tuberculosis rifampicin-resistant tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY TUBERCULOSIS

Contacts and locations

Locations

  • Bio-Medical Research Institute; Faculty of Medicine and Health Sciences, Stellenbosch University; Tygerberg Medical Campus

    Cape Town, South Africa

  • CHRU - Durban

    Durban, South Africa

  • Clinical HIV Research Unit (CHRU) - Johannesburg

    Johannesburg, South Africa

  • Lung Center of the Philippines

    Quezon City, Philippines

  • Perinatal HIV Research Unit (PHRU)

    Klerksdorp, South Africa

  • Silang Specialist Medical Center

    Silang, Philippines

  • Synergy Biomed Research Institute

    East London, South Africa

  • TASK - Central (Brooklyn)

    Cape Town, South Africa

  • The Aurum Institute (Tembisa CRS)

    Johannesburg, South Africa

  • Tropical Disease Foundation

    Makati, Philippines

  • UCT (Cape Town); General Medicine & Global Health (GMGH); Hatter Heart Research Institute

    Cape Town, South Africa

  • UCT South African Tuberculosis Vaccine Initiative (SATVI)

    Cape Town, South Africa

  • University of Cape Town (UCT) Lung Institute

    Cape Town, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.